Skip to main content

Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure.

Publication ,  Journal Article
Baghdadi, JD; Wessel, M; Dubberke, ER; Lydecker, A; Claeys, KC; Alonso, C; Coffey, KC; Durkin, M; Gonzales-Luna, AJ; Guh, AY; Kwon, JH ...
Published in: Antimicrob Steward Healthc Epidemiol
2024

BACKGROUND: Clostridioides difficile infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact of signs, symptoms, and healthcare exposures on pre-test likelihood of CDI. METHODS: A panel of fifteen experts in infectious diseases participated in a modified UCLA/RAND Delphi study to estimate likelihood of CDI. Consensus, defined as agreement by >70% of panelists, was assessed via a REDCap survey. Items without consensus were discussed in a virtual meeting followed by a second survey. RESULTS: All fifteen panelists completed both surveys (100% response rate). In the initial survey, consensus was present on 6 of 15 (40%) items related to risk of CDI. After panel discussion and clarification of questions, consensus (>70% agreement) was reached on all remaining items in the second survey. Antibiotics were identified as the primary risk factor for CDI and grouped into three categories: high-risk (likelihood ratio [LR] 7, 93% agreement among panelists in first survey), low-risk (LR 3, 87% agreement in first survey), and minimal-risk (LR 1, 71% agreement in first survey). Other major factors included new or unexplained severe diarrhea (e.g., ≥ 10 liquid bowel movements per day; LR 5, 100% agreement in second survey) and severe immunosuppression (LR 5, 87% agreement in second survey). CONCLUSION: Infectious disease experts concurred on the importance of signs, symptoms, and healthcare exposures for diagnosing CDI. The resulting risk estimates can be used by clinicians to optimize CDI testing and treatment.

Duke Scholars

Published In

Antimicrob Steward Healthc Epidemiol

DOI

EISSN

2732-494X

Publication Date

2024

Volume

4

Issue

1

Start / End Page

e168

Location

England
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baghdadi, J. D., Wessel, M., Dubberke, E. R., Lydecker, A., Claeys, K. C., Alonso, C., … CDC Prevention Epicenters Program. (2024). Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure. Antimicrob Steward Healthc Epidemiol, 4(1), e168. https://doi.org/10.1017/ash.2024.387
Baghdadi, Jonathan D., Mia Wessel, Erik R. Dubberke, Alison Lydecker, Kimberly C. Claeys, Carolyn Alonso, K. C. Coffey, et al. “Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure.Antimicrob Steward Healthc Epidemiol 4, no. 1 (2024): e168. https://doi.org/10.1017/ash.2024.387.
Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, et al. Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e168.
Baghdadi, Jonathan D., et al. “Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure.Antimicrob Steward Healthc Epidemiol, vol. 4, no. 1, 2024, p. e168. Pubmed, doi:10.1017/ash.2024.387.
Baghdadi JD, Wessel M, Dubberke ER, Lydecker A, Claeys KC, Alonso C, Coffey KC, Durkin M, Gonzales-Luna AJ, Guh AY, Kwon JH, Martin E, Mehrotra P, Polage CR, Pulia MS, Rock C, Skinner AM, Vaughn VM, Vijayan T, Yarrington ME, Morgan DJ, CDC Prevention Epicenters Program. Informing estimates of probability of Clostridioides difficile infection for testing and treatment: expert consensus from a modified-Delphi procedure. Antimicrob Steward Healthc Epidemiol. 2024;4(1):e168.

Published In

Antimicrob Steward Healthc Epidemiol

DOI

EISSN

2732-494X

Publication Date

2024

Volume

4

Issue

1

Start / End Page

e168

Location

England